Product
Anti-PD-1/PD-L1 treatment
1 clinical trial
4 indications
Indication
OncologyIndication
Non-Small Cell Lung Cancer Stage IVIndication
NSCLCIndication
Stage IIIClinical trial
A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of Pembrolizumab +/- UV1 Vaccination as First Line Treatment in Patients With Inoperable Advanced or Metastatic Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-07-01